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Summary
Dendritic cells are highly adapted to their role of presenting antigen and
directing immune responses. Developmental studies indicate that DCs ori-
ginate independently from monocytes and tissue macrophages. Emerging
evidence also suggests that distinct subsets of DCs have intrinsic differ-
ences that lead to functional specialisation in the generation of immu-
nity. Comparative studies are now allowing many of these properties to
be more fully understood in the context of human immunology.
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Introduction
The orchestration of effective immunity in vertebrates
depends upon dendritic cells (DCs), a class of bone-mar-
row-derived cells found in the blood, epithelia and lym-
phoid tissues. DCs are equipped with molecular sensors
and antigen-processing machinery to recognize pathogens,
integrate chemical information and guide the specificity,
magnitude and polarity of immune responses. Recent
advances have helped to define DCs as a distinct haemat-
opoietic lineage and to establish functional specialization
between different DC subsets. The aim of this review is to
present a coherent framework for understanding human
DC subsets and their functional roles in vivo.
How are DCs distinct from monocytes and
macrophages?
Dendritic cells, monocytes and macrophages traditionally
comprise the mononuclear phagocyte system. An emerging
theme is that components of this system are not as related
as was presumed a decade ago. The phenotypic differences
between human DCs and macrophages are discernible by
immunohistochemistry1,2 and a clear functional distinc-
tion is the ability of DCs to leave tissues while macrophag-
es remain fixed. This property may be tested directly by
explanting tissue in vitro, and is mirrored by significant
differences in turnover between DCs and macrophages
after stem cell transplantation in vivo.3
More recently, the taxonomy of DC populations and
their homology to mouse DC subsets have been scruti-
nized by transcriptional profiling.4–11 This has been
assisted by a large and systematic effort to profile human
and mouse leucocytes (Biogps; Immgen, www.biogps.org,
www.immgen.org).12,13 Principal component analysis con-
veniently displays multidimensional data in a format
familiar to flow cytometrists and reveals that quiescent
primary DCs form discrete populations separate from
monocytes (Fig. 1). This accords with ontogenetic studies
in mice showing that most steady-state DCs are derived
from committed DC-restricted precursors independently
of monocytes.14
The power of this approach is that it offers an unbiased
assessment of relationships between cells rather than reli-
ance upon a small selection of markers. The pitfalls in
relation to DC lineage studies are that hierarchical clus-
tering and principal component analysis are exquisitely
sensitive to tissue-specific effects arising during prepara-
tion; this can easily obscure the relationships between
similar DCs isolated from different sources. These effects
can be minimized by bioinformatic strategies based on gene
set enrichment analysis in which subset-specific signatures
are identified or tissue-specific gene sets are removed before
analysis. Most tissue-specific effects are the result of differ-
ent states of maturation. It has recently been shown that
strong activating stimuli induce convergence of DC
transcriptional profiles through nuclear factor-jB and inter-
feron-inducible pathways and naturally tend to obscure
ontogenetic differences in transcriptional profiles.15
Overview of human dendritic cell lineages
Recent comparative phenotypic and functional studies
have delineated a small number of distinct DC subsets
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that are widely distributed in all mammals (Table 1). In
humans, all DCs express high levels of MHC class II
(HLA-DR) and lack typical lineage markers CD3 (T cell),
CD19/20 (B cell) and CD56 (natural killer cell). The clas-
sical descriptions of DCs as HLA-DR+ lineage cells have
been refined to include a number of positive DC lineage
markers that identify DCs as either ‘myeloid’ or ‘plasma-
cytoid’ according to recent convention.16
Myeloid DCs (mDCs)
Myeloid DCs (mDCs) express typical myeloid antigens
CD11c, CD13, CD33 and CD11b, corresponding to
mouse CD11c+ ‘classical’ or ‘conventional’ DCs. In
humans both monocytes and mDCs express CD11c, but
DCs lack CD14 or CD16 and may be split into CD1c+
and CD141+ fractions. These two fractions share homol-
ogy with mouse classical DCs expressing either CD11b
(CD1c+ DCs) or CD8/CD103 (CD141+ DCs).
Plasmacytoid DCs (pDCs)
Plasmacytoid DCs (pDCs) typically lack myeloid antigens
and are distinguished by expression of CD123, CD303
and CD304. Although not related directly to plasma cells
they retain subtle lymphoid features and unique secretory
properties. Homologues are recognized in many species.
CD14+ DCs
CD14+ DCs found in tissues and lymph nodes are a third
subset of CD11c+ myeloid cells originally described as
‘interstitial DCs’. They are more monocyte-like or macro-
phage-like than CD1c+ and CD141+ mDCs and may arise
from classical monocytes. Equivalent cells have recently
been found in mice as a new monocyte-derived subset of
CD11b classical DCs that expresses or ESAM.
Langerhans cells (LCs) and microglia
Langerhans cells (LCs) and microglia are two specialized
self-renewing DC populations found in stratified squamous
epithelium and parenchyma of the brain, respectively. The
LCs are capable of differentiating into migratory DCs
whereas microglia are considered as a type of macrophage
by many authors. Recent reviews provide excellent summa-
ries of microglia and they will not be discussed further.17
Functional–anatomical classification of dendritic
cells
A functional–anatomical classification derived from mur-
ine studies recognizes that DC function is intimately
linked to location.18 Primarily this separates ‘migratory’
DCs that have trafficked through the tissues, from ‘resi-
dent’ DCs that arise in lymph nodes directly from the
blood. Two further compartments also merit consider-
ation: blood DCs and inflammatory DCs. The distribu-
tion of human DC subsets is summarized in Fig. 2.
Blood/precursor DCs
Blood DCs are well defined in humans, and are likely to be
precursors of tissue and lymphoid organ DCs. In support of
this, blood contains pDCs, CD1c+ and CD141+ mDCs in
immature forms of those found in tissues and lymph
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Figure 1. Transcriptional profiling of blood monocytes and dendritic cells (DCs). (a) Principal component analysis; (b) Connectivity mapping
(cMAP) of gene set enrichment. The prinicipal components (PCs) are vectors that account for most of the variability in the populations and
illustrate the clustering of all monocyte populations separately from DCs. Plasmacytoid DCs have the most distinct DC signature and cluster away
from the two myeloid DCs and the monocyte cluster. The percentage variation accounted for by PC1 and PC2 in the example shown is 326%
and 137%, respectively. Connectivity mapping defines the enrichment of different populations for a given gene signature. The cMAP enrichment
score is a scalar quantity normalized to the index gene signature. The example shows the enrichment of monocyte and DC transcriptional profiles
for the CD14 monocyte signature, illustrating the relatedness of all monocyte populations, intermediate status of CD1c+ DCs and distant rela-
tionship of CD141+ DCs and pDCs. The gene signature of each population is defined by those genes whose expression exceeds an average
obtained from all the other populations. Each point represents a biological replicate (n = 6). Data replotted from ref. 8 courtesy of Pavandip
Wasan, Michael Poidinger and Florent Ginhoux (Singapore Immunology Network).
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nodes.19,20 Mice also have blood pDCs and circulating precur-
sors of classical DCs known as pre-cDCs. Pre-cDCs are blood
mDCs in all but name and comprise multiple subsets that
may correspond to the two human myeloid blood DCs.21
Non-lymphoid/tissue/migratory DCs
Most epithelial tissues contain ‘non-lymphoid’ or ‘migra-
tory’ DCs whose function is to acquire antigen and migrate
via the afferent lymphatics to lymph nodes. Quiescent inter-
stitial tissues contain CD1c+ mDCs, CD141+ mDCs and
CD14+ DCs but few pDCs.8,22 Epidermal LCs also migrate
to form a component of afferent lymphatic DCs23 but it
remains uncertain whether CD14+ DCs are migratory.24
Lymphoid/resident DCs
Lymphoid tissue also contains a large cohort of blood-
derived non-migratory ‘lymphoid’ or ‘resident’ DCs. In the
steady state, these may be difficult to separate from migra-
tory DCs derived from the tissues. Human lymphoid tissue
is less well described than mouse but contains CD1c+
mDCs, CD141+ mDCs and pDC in the steady state, in
addition to a number of CD14+ populations.8,22 The con-
tingent of resident lymphoid and migratory DCs in lymph
nodes increases markedly during inflammation.
Inflammatory DCs
The content of tissues and lymphoid organs is dramati-
cally altered during inflammation principally by the
recruitment of granulocytes, classical monocytes and
pDCs. Steady-state DC populations become more difficult
to detect either because they migrate or are diluted by
recruited cells. CD14+ classical monocytes are the putative
precursors of inflammatory DCs. It is not known whether
blood DCs are also recruited during inflammation but
expression of CD62L and CXCR3, (receptor for inter-
feron-c-inducible chemokines CXCL9,10,11) suggests that
they are competent to extravasate. Recent work confirms
that inflammatory exudates contain two populations with
polarized DC and macrophage properties.9 The relative
contributions of migrating tissue DCs and newly recruited
inflammatory DCs to the initiation of immunity, is a crit-
ical unresolved problem in humans.
CD1c+ myeloid DCs
CD1c+ mDCs are the major population of human mDCs
in blood, tissues and lymphoid organs. They were origi-
nally recognized in the blood as a fraction of HLA-DR+
lineage− cells expressing myeloid antigens CD11b, CD11c,
CD13, CD33, CD172 (SIRPa) and CD45RO25 and
Table 1. Human mouse homology.
Human Mouse
CD1c+
Dectin 1 (CLEC 7A)
Dectin 2 (CLEC6A)
CD141+
CLEC9A
XCR1
CD11b+ (tissues)
CD4+ CD11b+ (lymphoid)
ESAM
CD103+ (tissues)
CD8+ (lymphoid)
CLEC9A
XCR1
Langerin
Plasmacytoid
CD14+ DC
CD209 (DC-SIGN)
Factor XIIIA
CD11b+ CD64+ tissue DC
CX3CR1
CD14
CD303 (CLEC4C)
CD304 (neuropilin)
CD123 (IL-3R)
Monocyte-related
Inflammatory DC
CD1c
CD16 negative
CD16+ monocyte
CX3CR1hi
SLAN (subset)
Gr-1/Ly6C low monocyte
CX3CR1hi
CCR2 negative
Monocyte-derived DC
CD209 (DC-SIGN)
CD206
B220
Siglec H
Major subset
Myeloid/Classical
Cross-presenting
Refs
(8, 10, 11, 82, 83)
(8, 35, 37, 40, 41, 54)
(5, 6, 19, 20, 57)
(3, 56, 75, 76)
(20, 84, 85)
(9, 53, 81, 82, 83, 84)
Surface markers of the major human DC populations and their murine homologues. Myeloid DCs and mouse classical DCs (also known as con-
ventional DCs) contain a major subset and a minor specialised cross-presenting subset. Plasmacytoid DCs are easily recognisable in many species.
Monocyte related DCs include a recently recognised subset of CD11b+ DCs that may be homologous to human CD14+ DCs. Inflammatory
monocyte-derived DCs are also recognised in both species but are heterogeneous.
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comprise approximately 1% of mononuclear cells, usually
slightly lower than pDCs. CD1c was identified as a useful
marker by the commercial antibody BDCA-1.19
In tissues, dermal CD1c+ DCs were originally described
as the HLA-DR+ ‘indeterminate’ cell by electron micro-
scopy (EM)26 and later characterized as CD1a+ DCs
migrating from in vitro explants.27,28 Although dermal
CD1c+ DCs and LCs both express CD1a, LCs may be
identified by Langerin, epithelial cell adhesion molecule
(EpCAM) and higher CD1a expression.1,3,29
Human tissue CD1c+ DCs appear more activated than
their blood counterparts in terms of expression of
CD80, CD83, CD86 and CD40. They have lost expres-
sion of homing receptors CLA and CD62L but up-regu-
lated CCR7.1,29,30 A potential precursor–progeny
relationship between blood and tissue CD1c+ DCs is
supported by recent in vitro differentiation and gene
expression analysis.8 This model is not universally
accepted on the grounds that simple hierarchical cluster-
ing fails to discern any lineage relationship between
blood and skin.11
In lymph nodes, CD1c+ DCs are found as ‘interdigitat-
ing cells’ of T-cell areas. Variable expression of CD1a and
Langerin in skin-draining nodes suggests that both CD1c+
DCs and LCs contribute to this population.31–33 Tonsil
and spleen also contain CD1c+ DCs.34–36 As these tissues
do not receive afferent lymph, it is concluded that some
CD1c+ DCs are ‘resident DCs’ originating directly from
the blood.8,37
CD1c+ DCs are equipped with a wide range of lectins,
toll-like receptors (TLRs) and other pattern recognition
receptors for general purpose antigen uptake, transport
and presentation. Through TLRs 1–8 they respond well to
lipopolysaccharide, flagellin, poly(IC) and R848.38 The
potential of CD1c and CD1a to present the glycolipid
antigens of mycobacteria and other pathogens is often
overlooked.39 Dectin-1 (CLEC7A) and Dectin-2
(CLEC6A) are highly expressed, suggesting a role in fungal
recognition.10,11 DEC205 (CD205; CLEC13B) and macro-
phage mannose receptor (CD206; CLEC13D) are vari-
able.22 CD1c+ DCs are good stimulators of naive CD4 T
cells but have inferior capacity to cross-present antigen to
CD8 T cells compared with CD141+ DCs.8,35,37,40,41 They
secrete tumour necrosis factor-a (TNF-a), interleukin-8
(IL-8) and IL-10 when stimulated and produce IL-12 in
response to TLR7/8 ligation by R848.36 A small amount of
IL-23 can be detected after a range of stimuli.42 This
implies a dual role in T helper type 1 (Th1) and Th17
sensitization and highlights the plasticity of DCs in differ-
ent contexts. Deletion of the equivalent CD11b DC subset
of mice leads to a range of functional deficits in Th1, Th2
and Th17 immunity (reviewed in ref. 43).102
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Figure 2. The distribution of major human dendritic cell (DC) subsets in blood, epithelial tissues and lymph nodes. Broken arrows indicate rela-
tionships that require further confirmation in humans. Human DCs can be generated either from granulocyte–macrophage progenitors (GMP)
or multi-lymphoid progenitors (MLP) both of which ultimately arise from haematopoietic stem cells (HSC). Classical monocytes, blood myeloid
DC (mDC) and plasmacytoid DC (pDC) are putative precursors of tissue and lymphoid DCs. Non-classical monocytes are reported to arise by
conversion of classical monocytes in the mouse. Inflammatory DCs and CD14+ DCs have transcriptional profiles suggesting that they arise from
monocytes; likewise tissue CD1c+ DCs and CD141+ DCs are related to their blood counterparts. Myeloid DCs and Langerhans cells (LCs) both
form interdigitating cells in skin-draining lymph nodes. CD14+ DCs and pDCS are also found in nodes but may arise directly from the blood
rather than by migration from tissues.
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CD141high myeloid dendritic cells
The expression of CD141 or thrombomodulin on approx-
imately 10% of human blood mDCs (01% of mononu-
clear cells) was noted over a decade ago with the
development of the blood DC antibody BDCA-3.19,20
CD141+ DCs have also been found among resident DCs
of lymph node, tonsil, spleen and bone marrow22,35–37
and non-lymphoid tissues, skin, lung and liver.8
CD141+ DCs are difficult to identify in situ owing to
their small numbers and the wide expression of CD141
on other cells.37 In particular, CD141 is found on migra-
tory CD14+ DCs and on CD1c+ DCs and monocytes cul-
tured with vitamin D.44 Differentiation from the major
CD1c+ DC subset by flow cytometry is aided by the
observation that CD141+ DCs express less CD11b and
CD11c.8,45
The realisation that human CD141+ DCs are homolo-
gous to mouse CD8+ lymph node DCs35,37,40,41 and
CD103+ tissue DCs8 is something of a Rosetta stone in
DC biology, enabling the systematic alignment of human
and mouse DC subsets across lymphoid and non-lym-
phoid tissues. Both CD141+ and CD8+ DCs have acquired
the status of ‘cross-presenting’ DCs in comparison with
other myeloid or classical DCs.46 Comparative biology
approaches have also identified CLEC9A,47–49 XCR1,50
Necl251 and TRL3 expression52 as a concise functional
profile that species barriers. DEC205, a marker of CD8+
mouse DCs, is not restricted to human CD141+ DCs but
XCR1 and CLEC9A have emerged as universal markers of
cross-presenting DCs in multiple species.45,50
CD141+ mDCs have an enhanced ability to take up
dead or necrotic cells via CLEC9A,40,49 sense viral nucleic
acids with TLR3 and TLR8 and to cross-present antigen
to CD8+ T-cell clones in vitro.8,35,37,40 This function is
consistent with their homology to mouse CD8+/CD103+
DCs, although CD141+ DCs show less enrichment for
gene transcripts controlling class I presentation than the
homologous mouse DCs.6 CD141+ DCs readily secrete
TNF-a, CXCL10 and interferon-k but surprisingly little
IL-12 p70, in contrast to mDCs and CD1c+ DCs.8,36,53,54
Notably, other populations of human DCs derived
in vitro are also capable of cross-presentation, especially
LC-like cells differentiated in granulocyte–macrophage
colony-stimulating factor (GM-CSF) and TNF-a.55,56
Overall, the division of labour between CD141+ DCs and
other myeloid DCs appears less sharply demarcated than
in the mouse, a reminder that functional cross-species
comparison is an imprecise science.
Plasmacytoid dendritic cells
Plasmacytoid DCs have unique specialized functions that
have been extensively reviewed.57 The most numerous
blood DCs, they lack myeloid antigens CD11b, CD11c,
CD13 and CD33 but express CD45RA, variable CD2 and
CD7 and may harbour T-cell receptor and immunoglobu-
lin rearrangements. The morphological epithet ‘
plasmacytoid’ reflects abundant secretory capacity and
avoids the anatomical connotations of ‘lymphoid’. Plas-
macytoid DCs are now separable from mDCs by positive
markers CD123 (IL-3R), CD303 (CLEC4C; BDCA-2) and
CD304 (neuropilin; BDCA-4).19 They are not abundant
in quiescent tissues but are present in LN at about 20%
of MHC class II positive cells and are rapidly recruited to
both sites in inflammation.58
The propensity of pDCs to release type 1 interferon in
response to viruses was one of the first specialized DC
functions to be described.59–61 They express very high lev-
els of TLR7 and TLR9, which transduce signals from viral
and self nucleic acids.62,63 Freshly isolated blood pDCs do
not prime naive T cells efficiently and appear less ‘mature’
than mDCs until activated.60,61,64 Their ability to polarize
CD4 responses towards Th1 or Th2 is variable and may
be context-dependent.65,66 In other systems pDC have
been reported to induce regulatory T cells or tolerance,
possibly related to their ability to sense DNA released
from apopotic cells and notable expression of ILT7.67,68
Failure of tolerance is linked to the autoimmune diseases
systemic lupus erythematosus and psoriasis.63
CD14+ dendritic cells
Many non-lymphoid tissues contain a modest population
of CD14+ HLA-DR+ cells that express CD11c in common
with monocytes but lack typical mDC markers such as
CD1c or CD141, co-stimulatory molecules and
CCR7.3,29,56 These cells were originally identified as
migrant CD14+ populations from human skin.27,28 They
were previously referred to as ‘interstitial-type’ or ‘der-
mal-type’ DCs (to contrast with epidermal LCs) but this
term is misleading because it ignores the major popula-
tion of CD1c+ interstitial mDCs.
CD14+ DCs express DC-SIGN (CD209) and the macro-
phage markers FXIIIA and CD163, which may also be
found on monocytes or monocyte-derived DCs and macro-
phages, especially those generated under tolerogenic condi-
tions such as IL-10 or vitamin D.3,69,70 In situ, it can be
difficult to separate CD14+ DCs from macrophages by anti-
gen expression and recourse to the physical properties of
side scatter, autofluorescence and ability to migrate from
explanted skin, is required.3 Somewhat confusingly, CD14+
DCs acquire CD141 in culture but otherwise they do not
resemble cross-presenting CD141+ DCs, which are typically
CD14 negative and cannot be made from monocytes.
CD14+ DCs migrating from explanted human skin are
less mature or more macrophage-like than CD1c+ DCs
and do not stimulate naive T cells efficiently.8,29,71,72
CD14+ DCs retain the ability to differentiate into LC-like
cells or more mature DC-like cells in vitro.42,71,73 Unstim-
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ulated they have proven tolerogenic functions that can be
recapitulated by treating monocytes with vitamin D.44
Together these properties suggest that CD14+ DCs may
be extravasated, quiescent ‘tissue monocytes’. Their turn-
over in bone marrow transplantation is rapid, and paral-
lels blood myeloid engraftment, in contrast to long-lived
macrophages.3
As CD14+ DCs express little CCR7, their migration to
lymph nodes is questionable3,29 although discrete, possi-
bly blood-derived CD14+ CD209+ cells are found in the
paracortex.22,32 Important functions have been ascribed to
CD14+ DCs in the formation of follicular helper T cells56
or in providing direct B-cell help.74
The mouse equivalent of CD14+ DCs is currently under
scrutiny. As suspected from human biology, non-lym-
phoid tissue CD11b+ DCs are heterogeneous and contain
monocyte-derived cells with properties similar to CD14+
DCs. New markers including CD24, CD26, CD64 and
CX3CR1 are allowing a monocyte-derived component of
the CD11b DC population to be identified.75,76 Further
confirmation of this would suggest by correlation, that
CD14+ human DCs are indeed monocyte-derived and
shed new light on their in vivo function.
Langerhans cells
Langerhans cells reside in the supra-basal epidermis and
other stratified squamous epithelia (bronchus, oral and
genital mucous membrane) where they form a network.
Human LCs express high levels of the C-type lectin Lang-
erin and CD1a, a non-polymorphic class I MHC mole-
cule. Both antigen capture and presentation molecules are
found together in a specialized endosomal compartment,
visible by EM as the Birbeck granule. Other markers
include CD36, ATPase and FceR1.23,77
Langerhans cells epitomize migratory tissue DC and have
facilitated many studies of functional DC specialization
across several species.23 Their derivatives can easily be
detected in skin-draining lymph nodes, especially in inflam-
matory skin disorders. They occupy the lymph node para-
cortex as langerin+ CD1ahigh interdigitating cells.78
The function of LCs in immunity has been surprisingly
difficult to pin down. They can be matured into potent
cross-presenting DCs39 but also lack critical TLRs and
can induce regulatory T cells and IL-22 production
through CD1a-restricted antigen to autologous T cells.79
Overall, LCs appear to maintain epidermal health and
tolerance to commensals, while retaining the ability to
respond to selected intracellular pathogens and viruses
under inflammatory conditions.
Inflammatory dendritic cells
It has been known for many years that highly functional
DCs can be derived from classical CD14+ blood mono-
cytes, using GM-CSF and IL-480 or more subtle in vitro
tissue models.24 Monocyte-derived DCs have a wide range
of properties including potent stimulation of naive CD4+
T cells, cross-presentation to CD8+ T cells and produc-
tion of key cytokines IL-1, IL-6, TNF-a, IL-12 and
IL-23.53
With correlative evidence that most primary DCs are
probably not derived from monocytes, the challenge is to
understand the role of inflammatory monocyte recruit-
ment to human DC biogenesis in vivo. Monocytes are
highly plastic and their differentiation into DCs or differ-
ent forms of macrophages (M1/M2) in vitro provides a
conceptual framework for inflammation. Human inflam-
matory exudates contain distinct inflammatory DC-like
and macrophage-like cells and transcriptional profiling
suggests a common monocyte origin.9 Key features of
these cells are the expression of CD1c, CD1a, CD206,
FceR1, SIRPa but lack of CD16 and CD209. In vitro they
synthesize IL-1b, TNF-a, IL-6 and IL-23 and stimulate
Th17 responses. Monocyte-derived DCs and inflamma-
tory DCs in this study both express transcription factor
zbtb46, in common with CD1c+ DCs.81,82 Previous
descriptions of inflammatory DCs include inflammatory
dendritic epidermal cells (IDECs), found in Th2-mediated
atopic dermatitis, and TNF and inducible nitric oxide
synthase-producing (TiP) DCs, found in psoriasis.83,84
Together these data suggest that different inflammatory
environments will generate monocyte-derived DC subsets
with distinct functions. Many questions remain, including
whether blood DCs also form inflammatory cells directly
and whether inflammatory DCs migrate to lymph nodes
or differentiate into steady-state resident cells after resolu-
tion of inflammation.
Non-classical monocytes and SLAN DCs
Human monocyte populations are heterogeneous16 and
CD16+ monocytes possess distinct characteristics includ-
ing higher MHC class II and co-stimulatory antigen
expression that have led some authors to classify them
as a type of blood DC.20 In agreement with this view, a
subset of CD16+ monocytes characterized by expression
of the antigen 6-Sulpho LacNAc (SLAN) is reported to
secrete large amounts of TNF-a, IL-1b and IL-12 and to
respond rapidly to inflammatory stimuli.84 There is a
lack of consensus, however. Gene expression analysis
and functional studies suggest that CD16+ CD14dim
non-classical monocytes, including SLAN+ cells, have
low inflammatory activity and are homologous to mur-
ine Gr-1/Ly6C low ‘patrolling’ monocytes.85 In this
report, cytokine secretion and pro-inflammatory activity
were attributed to intermediate CD14+ CD16+ mono-
cytes. Anatomically, non-classical CD16+ monocytes are
well positioned to infiltrate tissues but it remains uncer-
tain that they should be classified as DCs. Unsupervised
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hierarchical clustering of gene expression data is
unequivocal that all monocytes cluster independently of
DCs.5,8,10,11
Origin of human dendritic cells
Human DCs arise from the bone marrow through a series
of currently undefined precursors that may have both
myeloid and lymphoid ancestry.86 Bone marrow trans-
plantation and human DC deficiency states indicate that
continual replenishment from blood-borne precursors is
required for tissue populations of CD1c+, CD141+ and
CD14+ DCs.3,87,88 The potential role of blood DCs as pre-
cursors to tissue DCs has been outlined but there is a gap
in knowledge between the bone marrow and peripheral
blood compartments. Although Flt-3 and MHC class II
expression has been useful for tracking restricted DC pre-
cursors in the mouse, they are less informative markers in
humans because the entire CD34+ progenitor compart-
ment is positive.
Studies in humans with DC deficiency have begun to
shed some light on the cellular pathways and genetic reg-
ulation of DC haematopoiesis.88 By analogy with mice, it
is likely that the early transcription factors Ikaros, PU.1,
Gfi1 and Id2 are required for DC development in
humans.89,90 Ikaros and GFi1 defects have been character-
ized in humans but have much broader haematopoietic
defects than suggested by murine models. Heterozygous
GATA-2 mutation induces a specific defect in mononu-
clear cell development, known as DC, monocyte, B and
NK lymphoid (DCML) deficiency.91
Dendritic cell production from human progenitors is
promoted by Flt-3 ligand, GM-CSF and IL-4 in vitro35
and Flt-3, macrophage colony-stimulating factor (M-CSF)
and GM-CSF signalling via signal transducers and activa-
tors of transcription 3 and 5 is likely to play an impor-
tant role in vivo. Flt-3 is more highly expressed on DCs
than monocytes or macrophages, in inverse relationship
with M-CSF receptor.8 Functional GM-CSF deficiency
due to an autoimmune neutralizing antibody exists and
causes defective function of alveolar macrophages but DC
profiling has not been performed in detail.92
More specific defects in classical DCs have been
reported in mice lacking interferon regulatory factor 4
(IRF4), IRF8 and Batf3 and in pDCs due to loss of
E2-2.89,90 In particular the balance between Id2 and E2-2
is critical in specifying myeloid or plasmacytoid DC devel-
opment and E2-2-deficient humans have impaired pDC
function.57,93 Bi-allelic IRF8 deficiency in humans causes
loss of all DCs and monocytes, in keeping with a broader
pattern of human IRF8 expression than in mouse.94 Batf3
knock-down by lentiviral short hairpin RNA inhibits the
formation of CD141+ DCs, a result that is more closely
aligned to the selective loss of CD8+ DCs in knockout
mice.45 The recently described transcription factor zbtb46
is specifically expressed in mDCs but is not required for
the development of murine classical DCs.81,82
Human LCs have some self-renewal capacity indepen-
dently of the bone marrow. Several reports have shown
that they are proliferating cells95,96 maintained in a hair
follicle niche.97 Human limb transplants show that they
remain of donor origin, independent of the bone
marrow,98 although after haematopoietic stem cell
transplantation, they are gradually replaced by bone-mar-
row-derived cells.87 Humans lacking monocytes and all
identifiable DC populations also maintain reasonable LC
populations, ruling against monocytes or CD14+ dermal
DCs as steady-state precursors.91 The ready derivation of
LC-like cells from CD34+ bone marrow progenitors or
monocytes in vitro99,100 is in keeping with observations in
mice that blood-borne progenitors may be recruited to
renew LCs after severe inflammation has destroyed their
epidermal niches.101 The development of LCs reflects a
more macrophage-like ancestry than other DC popula-
tions. Treansforming growth factor-b is required for the
acquisition of langerin in humans and M-CSF receptor
rather than Flt-3 is critical for their development in mice.
Concluding remarks and future directions
Many years after the mononuclear phagocyte system was
conceived and monocyte-derived DCs were discovered in
humans, we perceive monocytes, macrophages and DCs
more clearly but acknowledge ever more complexity in their
origins and complementary functions. The specialized func-
tions of human DC subsets and their derivation from DC-
restricted precursors is beginning to be established and
should lead to new therapeutic opportunities. However,
much remains to be learned about DC haematopoiesis in
humans in the steady state, and the pathological conse-
quences of inflammatory generation of DCs from monocytes.
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